November 10th, 2026Updates on CTx-1301, NDA Resubmission After FDA Complete Response LetterCingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requestsRead more
November 19th, 2026sNDA Submitted: Caplyta for the Treatment of Bipolar ManiaJohnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania. Read more
November 18th, 20262027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSDLearn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more. Read more
November 17th, 2026Phase 3 Data Back Tau PET Agent Florquinitau F 18 for Detecting Neurofibrillary Tangles in Alzheimer DiseaseIn 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.Read more
November 17th, 2026Mixed Results From Phase 3 Data for AR1001 in Alzheimer DiseaseNew phase 3 data for a PDE-5 inhibitor in Alzheimer disease.Read more
November 16th, 2026Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive DisorderHLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as day 2.Read more
November 16th, 2026FDA Approves Igalmi for Agitation Associated With Schizophrenia, Schizoaffective Disorder, or Bipolar I or II DisorderThe FDA has approved dexmedetomidine (Igalmi) sublingual film for at-home use. Read more
November 13th, 2026Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and SchizophreniaReview the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.Read more